Skip to main content
SpringerLink
Log in

Biomolecular Staging: Reality or Future Perspective?

  • Chapter
Biotechnology in Surgery

Part of the book series: Updates in Surgery ((UPDATESSURG,volume 0))

  • 780 Accesses

Abstract

The prognosis of patients with colorectal cancer has to date been mainly predicted on the basis of clinical and histopathologic items, with the TNM stage appearing to be the most imp

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Compton C, Fenoglio-Preiser CM, Fielding LP (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference Colorectal Working Group. Cancer 88:1739–1757

    Article  CAS  PubMed  Google Scholar 

  2. Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6:308–312

    Article  CAS  PubMed  Google Scholar 

  3. Compton CC (2003) Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 6:376–388

    Article  Google Scholar 

  4. Treanor D, Quirke P (2007) Pathology of colorectal cancer. Clin Oncol 19:769–776

    Article  CAS  Google Scholar 

  5. Klump B, Nehls O, Okech T et al (2004) Molecular lesions in colorectal cancer: impact on prognosis? Int J Colorectal Dis 19:23–42

    Article  CAS  PubMed  Google Scholar 

  6. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA et al (2000) p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 88:1814–1819

    Article  CAS  PubMed  Google Scholar 

  7. Schwandner O, Schiedeck THK, Bruch H-P et al (2000) p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 36:348–356

    Article  CAS  PubMed  Google Scholar 

  8. Hilska M, Collan YU, Path FRC et al (2005) The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 48:2197–2208

    Article  PubMed  Google Scholar 

  9. Lan Y, Chang S, Li A et al (2007) p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 22:499–506

    Article  PubMed  Google Scholar 

  10. Grizzle WE, Manne U, Weiss HL et al (2002) Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, bcl-2, MUC-1 and p-27 (kip-1). Int J Cancer 97:403–409

    Article  CAS  PubMed  Google Scholar 

  11. Kressner U, Bjorheim J, Westring S (1998) ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer 34:518–521

    Article  CAS  PubMed  Google Scholar 

  12. Andreyev HJNA, Norman AR, Cunningham D et al (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90:675–684

    Article  CAS  PubMed  Google Scholar 

  13. McKay JA, Douglas JJ, Ross VG et al (2002) Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 196:386–393

    Article  CAS  PubMed  Google Scholar 

  14. Polakis P (2000) Wnt signalling and cancer. Genes Dev 14:1837–1851

    CAS  PubMed  Google Scholar 

  15. Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signalling. Cell 103:311–320

    Article  CAS  PubMed  Google Scholar 

  16. Ikeguchi M, Makimo M, Kaibara N (2001) Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma. J Surg Oncol 77:201–207

    Article  CAS  PubMed  Google Scholar 

  17. Jung A, Schrauder M, Oswald U et al. (2001) The invasion front of human colorectal adenocarcinomas shows co-localisation of nuclear beta-catenin, cyclin D1 and p16INK4A and is a region of low proliferation. Am J Pathol 159:1613–1617

    CAS  PubMed  Google Scholar 

  18. Xie D, Sham JS, Zeng WF et al (2003) Heterogeneous expression and association of betacatenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107:896–902

    Article  CAS  PubMed  Google Scholar 

  19. Araujo SE, Bernardo WM, Habr-Gama A et al (2007) DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 50:1800–1810

    Article  PubMed  Google Scholar 

  20. Berczi C, Bocsi J, Bartha I et al (2002) Prognostic value of DNA ploidy status in patients with rectal cancer. Anticancer Res 22:3737–3741

    PubMed  Google Scholar 

  21. Muto T, Bussey HJ, Morson BC (1975) The evolution of cancer of the colon and rectum. Cancer 36:2251–2270

    Article  CAS  PubMed  Google Scholar 

  22. Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532

    Article  CAS  PubMed  Google Scholar 

  23. Rodrigues NR, Rowan A, Smith ME et al (1990) p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87:7555–7559

    Article  CAS  PubMed  Google Scholar 

  24. Mutch MG (2007) Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol 96:693–703

    Article  PubMed  Google Scholar 

  25. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932

    Article  CAS  PubMed  Google Scholar 

  26. Samowitz WS, Albertsen H, Herrick J et al (2005) Evaluation of a large, population based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129:837–845

    Article  CAS  PubMed  Google Scholar 

  27. Qiu LX, Tang QY, Bai JL et al (2008) Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 123:2384–2389

    Article  CAS  PubMed  Google Scholar 

  28. Jover R, Zapater P, Castells A et al for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2009) The efficacy of adjuvant chemotherapy with 5-Fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45:365–373

    Article  CAS  PubMed  Google Scholar 

  29. Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254–1261

    Article  CAS  PubMed  Google Scholar 

  30. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671

    Article  CAS  PubMed  Google Scholar 

  31. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  32. Tahara E (2007) Growth factors and oncogenes in gastrointestinal cancers. In: Meyers RA (ed) Cancer. Wiley-VCH, Weinheim, pp. 286–296

    Google Scholar 

  33. Pang RWC, Joh JW, Johnson PJ (2008) Biology of hepatocellular carcinoma. Ann Surg Oncol 15:962–971

    Article  PubMed  Google Scholar 

  34. Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48:2047–2063

    Article  CAS  PubMed  Google Scholar 

  35. Wild CP, Montesano R (2009) A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention Cancer Lett 286:22–28

    CAS  Google Scholar 

  36. Mínguez B, Tovar V, Chiang D et al (2009) Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 25:186–194

    Article  PubMed  Google Scholar 

  37. Llovet JM, Ricci S, Mazzaferro V et al for the SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Google Scholar 

  38. Siegel AB, Cohen EI, Ocean A et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992–2998

    Article  CAS  PubMed  Google Scholar 

  39. Bardeesy N, DePinho RA (2002) Pancreatic cancer biology and genetics. Nature 2:897–909

    CAS  Google Scholar 

  40. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2696–2972

    Google Scholar 

  41. Yamashita S (2009) Molecular targeted therapy for thyroid cancer in Japan: a call to reduce the backlog. Endocr J 56:919–920

    Article  PubMed  Google Scholar 

  42. Chevillard S, Ugolin N, Vielh P et al (2004) Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res 10:6586–6597

    Article  CAS  PubMed  Google Scholar 

  43. Hou P, Ji M, Xing M (2008) Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113:2440–2447

    Article  CAS  PubMed  Google Scholar 

  44. Smallridge RC, Marlow LA, Copland JA (2009) Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17–44

    Article  CAS  PubMed  Google Scholar 

  45. Polyak K (2008) Is breast tumor progression really linear? Clin Cancer Res 14:339–341

    Article  PubMed  Google Scholar 

  46. Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155–3163

    Article  CAS  PubMed  Google Scholar 

  47. Di Cosimo S (2009) Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy. Breast Cancer Research 11[Suppl 3]: S25

    Article  PubMed  Google Scholar 

  48. Seni T, Jatoi I (2008) An overview of the role of prophylactic surgery in the management of individuals with a hereditary cancer predisposition. Surg Clin N Am 88:739–758

    Article  Google Scholar 

  49. Schellhaas E, König C, Frank-Raue K et al (2009) Long-term outcome of “prophylactic therapy” for familial medullary thyroid cancer. Surgery 146:906–912

    Article  PubMed  Google Scholar 

  50. Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353:1105–1113

    Article  CAS  PubMed  Google Scholar 

  51. Guillem JG, Wood WC, Moley JF et al (2006) ASCO/SSO Review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24:4642–4660

    Article  PubMed  Google Scholar 

  52. Meijers-Heijboer H, Van Geel B, van Putten WLJ et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164

    Article  CAS  PubMed  Google Scholar 

  53. Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch Syndrome. N Engl J Med 354:261–269

    Article  CAS  PubMed  Google Scholar 

  54. Ramsoekh D, Wagner A, van Leerdam ME et al (2009) Cancer risk in MLH1, MSH1 and MSH6 mutation carriers; different risk profile may influence clinical management. Hered Cancer Clin Pract 23:17

    Article  Google Scholar 

  55. Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic development. J Surg Oncol 90:114–133

    Article  CAS  PubMed  Google Scholar 

  56. Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681

    Article  PubMed  Google Scholar 

  57. Schulte am Esch J, Knoefel WT, Klein M et al (2005) Portal application of autologous CD 133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cell 23:463–470

    Article  Google Scholar 

  58. Fürst G, Schulte am Esch J, Poll LW et al (2007) Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology 243:171–179

    Article  PubMed  Google Scholar 

  59. Kuhlmann KF, van Till JW, Boermeester MA et al (2007) Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:886–891

    Article  CAS  PubMed  Google Scholar 

  60. Yan L, McFaul C, Howes N et al (2005) Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128:2124–2130

    Article  CAS  PubMed  Google Scholar 

  61. Walgenbach KJ, Voigt M, Riabikhin AW et al (2001) Tissue engineering in plastic reconstructive surgery. Anat Rec 263:372–378

    Article  CAS  PubMed  Google Scholar 

  62. Mizuno H (2009) Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch 76:56–66

    Article  PubMed  Google Scholar 

  63. Yoshimura K, Sato K, Aoi N et al (2008) Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. Aesth Plast Surg 32:48–55

    Article  Google Scholar 

  64. Bechi P, Balzi M, Becciolini A et al (1996) Helicobacter pylori and cell proliferation of the gastric mucosa: possible implications for gastric carcinogenesis. Am J Gastroenterol 91:271–276

    CAS  PubMed  Google Scholar 

  65. Bechi P, Balzi M, Becciolini A et al (1991) Gastric cell proliferation kinetics and bile reflux after partial gastrectomy. Am J Gastroenterol 86:1424–1432

    CAS  PubMed  Google Scholar 

  66. Volpi A, De Paola F, Nanni O et al (2000) Prognostic significance of biologic markers in nodenegative breast cancer patients: a prospective study. Breast Cancer Res Treat 63:181–192

    Article  CAS  PubMed  Google Scholar 

  67. Amadori D, Nanni O, Volpi A et al (2008) Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelveyear results and retrospective subgroup analysis. Breast Cancer Res Treat 108:259–264

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Critical Care, University of Florence and Regional Reference Centre of Tuscany for Locoregional Perfusion Therapies, Florence, Italy

    Paolo Bechi

Authors
  1. Paolo Bechi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Anesthesiological, Surgical and Emergency Sciences, Second University of Naples, Naples, Italy

    Alfonso Barbarisi

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Italia

About this chapter

Cite this chapter

Bechi, P. (2011). Biomolecular Staging: Reality or Future Perspective?. In: Barbarisi, A. (eds) Biotechnology in Surgery. Updates in Surgery, vol 0. Springer, Milano. https://doi.org/10.1007/978-88-470-1658-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-1658-3_3

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-1657-6

  • Online ISBN: 978-88-470-1658-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation